EVUSHELD
Showing 1 - 19 of 19
Describe EVUSHELD™ Pre-exposure Prophylaxis in Real-world
Not yet recruiting
- COVID-19
- Evusheld
- (no location specified)
Dec 4, 2023
Israel Clalit Health Services
Not yet recruiting
- SARS-CoV-2
- COVID-19
- EVUSHELD
- (no location specified)
Jan 26, 2023
eVusheld Assessment reaL wORld Effectiveness at UPMC
Not yet recruiting
- SARS-CoV-2, COVID-19
- EVUSHELD
- (no location specified)
Dec 19, 2022
A Multi-Centre, Single-arm, Observational Study of EVUSHELD in
Active, not recruiting
- COVID-19
-
Qionghai, Hainan, China(2) Ruijin-Hainan Hospital Shanghai Jiaotong University School o
Jun 21, 2023
VA Health System
Not yet recruiting
- SARS-CoV-2, COVID-19
- Evusheld
- (no location specified)
Dec 15, 2022
A Non-interventional Multi-country Cohort Study to Assess Safety
Not yet recruiting
- Pregnancy
- +2 more
- (no location specified)
May 4, 2023
DoD Health System
Not yet recruiting
- COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
- EVUSHELD
- (no location specified)
Oct 4, 2022
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
Recruiting
- SARS-CoV-2 Infection
-
Aichi, Japan
- +2 more
Jan 17, 2023
EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in
Recruiting
- COVID-19
-
Abu Dhabi, United Arab Emirates
- +1 more
Jul 20, 2022
PREP (Pre-Exposure Prophylaxis) of COVID-19
Recruiting
- Immuno-Deficiency
- COVID-19
- Evusheld
-
Pittsburgh, PennsylvaniaUPMC
Aug 9, 2022
Chronic Lymphocytic Leukemia, COVID-19 Trial in Toronto (EVUSHELD)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- COVID-19
- EVUSHELD
-
Toronto, Ontario, CanadaSunnybrook Health Sciences Cente
Jul 18, 2022
Coronavirus Infections Trial in Moscow (tixagevimab/cilgavimab 150+150 mg, tixagevimab/cilgavimab 300+300 mg, regdanvimab)
Active, not recruiting
- Coronavirus Infections
- tixagevimab/cilgavimab 150+150 mg
- +2 more
-
Moscow, Russian FederationMoscow City Clinical Hospital 52
Aug 7, 2023
COVID-19, Immunodeficiency Trial (Paxlovid 5 days, Paxlovid 10 days, Tixagevimab and Cilgavimab)
Not yet recruiting
- COVID-19
- Immunodeficiency
- Paxlovid 5 days
- +2 more
- (no location specified)
Oct 18, 2022
COVID-19, SARS-CoV-2 Trial in Worldwide (AZD5156, Placebo, AZD7442 (EVUSHELD™))
Recruiting
- COVID-19, SARS-CoV-2
- AZD5156
- +2 more
-
Buenos Aires, Argentina
- +20 more
Jan 12, 2023
Coronavirus Disease 2019 (COVID-19), Healthy Volunteer Trial in Guangzhou, Shanghai (AZD7442 IM, Placebo IM, AZD7442 IV)
Active, not recruiting
- Coronavirus Disease 2019 (COVID-19)
- Healthy Volunteer
- AZD7442 IM
- +3 more
-
Guangzhou, China
- +1 more
Jul 27, 2022
SARS-CoV-2 Infection Trial in United States (Evusheld (tixagevimab+cilgavimab) IM or IV)
Recruiting
- SARS-CoV-2 Infection
- Evusheld (tixagevimab+cilgavimab) IM or IV
-
Fountain Valley, California
- +33 more
Jun 24, 2022
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies
Recruiting
- Immunocompromised Patients
- Data collection
-
Paris, Ile De France, FranceAssistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospita
Jul 5, 2022
COVID-19 Trial in France, Germany, United Kingdom (COVID-19 convalescent and vaccinated plasma, Current standard of care)
Recruiting
- COVID-19
- COVID-19 convalescent and vaccinated plasma
- Current standard of care
-
Besançon, France
- +10 more
May 3, 2022